As of Thursday close, Asensus Surgical Inc.’s (AMEX:ASXC) stock was down -$0.01, moving down -4.28 percent to $0.28. The average number of shares traded per day over the past five days has been 2,051,620 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0467 fall in that time frame. In the last twenty days, the average volume was 4,686,865, while in the previous 50 days, it was 3,400,260.
Since last month, ASXC stock retreated -1.47%. Shares of the company fell to $0.2600 on 09/21/23, the lowest level in the past month. A 52-week high of $1.18 was reached on 02/21/23 after having rallying from a 52-week low of $0.27. Since the beginning of this year, ASXC’s stock price has dropped by -20.71% or -$0.0719, and marked a new high 12 times. However, the stock has declined by -76.68% since its 52-week high.
ASXC stock investors should be aware that Asensus Surgical Inc. (ASXC) stock had its last reported insider trading activity 203 days ago on Mar 03. Biffi Andrea, the Director of the company, purchased of 293,077 shares for $0.71 on Mar 03. It resulted in a $207,557 investment by the insider.
Valuation Metrics
The stock’s beta is 1.62. Besides these, the trailing price-to-sales (P/S) ratio of 11.35, the price-to-book (PB) ratio of 1.06.
Financial Health
In the three months ended June 29, Asensus Surgical Inc.’s quick ratio stood at 4.30, while its current ratio was 5.20, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is -79.60% percent. Based on annual data, ASXC earned -$3.79 million in gross profit and brought in $7.09 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -76.30%. Return on equity (ROE) for the past 12 months was -90.10%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ASXC’s revenue rose 1.98% to $0.98 million during the quarter, while net income inched up to $1.01 million. While analysts expected Asensus Surgical Inc. to report -$0.08 quarterly earnings, the actual figure was -$0.09 per share, beating the consensus estimate by -12.50%. During the quarter, the company generated -$20.12 million in EBITDA. The liabilities of Asensus Surgical Inc. were 16.87 million at the end of its most recent quarter ended June 29, and its total debt was $5.48 million. The value of shareholders’ equity is $263.88 million.
Technical Picture
This quick technical analysis looks at Asensus Surgical Inc.’s (ASXC) price momentum. With a historical volatility rate of 71.64%, the RSI 9-day stood at 39.37% on 21 September.
With respect to its five-day moving average, the current Asensus Surgical Inc. price is down by -14.51% percent or -$0.0467. At present, ASXC shares trade -6.04% below its 20-day simple moving average and -57.00% percent below its 100-day simple moving average. However, the stock is currently trading approximately -44.40% below its SMA50 and -32.38% below its SMA200.
Stochastic coefficient K was 9.29% and Stochastic coefficient D was 14.06%, while ATR was 0.0307. Given the Stochastic reading of 10.91% for the 14-day period, the RSI (14) reading has been calculated as 40.30%. As of today, the MACD Oscillator reading stands at -0.0142, while the 14-day reading stands at -0.0204.
Analyst Ratings
Cantor Fitzgerald launched its rating on Asensus Surgical Inc. (AMEX: ASXC) to an Overweight in a note to investors on September 08, 2022. Asensus Surgical Inc. (ASXC) has been rated Buy by analysts. According to 0 brokerage firms, ASXC is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Asensus Surgical Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $1.50, the current consensus forecast for the stock is $1.00 – $2.00. Based on these forecasts, analysts predict Asensus Surgical Inc. (ASXC) will achieve an average price target of $1.50.
